My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 101

    1.

    Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.

    Ooi EM, Watts GF, Chan DC, Chen MM, Nestel PJ, Sviridov D, Barrett PH.

    Diabetes Care. 2008 Aug;31(8):1656-61. Epub 2008 May 28.PMID: 18509206 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.

    Ooi EM, Barrett PH, Chan DC, Nestel PJ, Watts GF.

    Atherosclerosis. 2008 Mar;197(1):139-46. Epub 2007 Apr 9.PMID: 17416370 [PubMed - indexed for MEDLINE]Related articles

    3.

    Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

    Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.

    Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1831-7. Epub 2008 Jun 19.PMID: 18566295 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.

    Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH.

    J Clin Endocrinol Metab. 2008 Feb;93(2):430-7. Epub 2007 Nov 20.PMID: 18029469 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

    Chan DC, Nguyen MN, Watts GF, Barrett PH.

    J Clin Endocrinol Metab. 2008 Feb;93(2):557-64. Epub 2007 Nov 13.PMID: 18000086 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

    Vergès B, Florentin E, Baillot-Rudoni S, Monier S, Petit JM, Rageot D, Gambert P, Duvillard L.

    Diabetologia. 2008 Aug;51(8):1382-90. Epub 2008 Jun 5.PMID: 18535816 [PubMed - indexed for MEDLINE]Related articles

    7.

    Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

    Diabetes. 2003 Mar;52(3):803-11.PMID: 12606523 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

    Vergès B, Florentin E, Baillot-Rudoni S, Petit JM, Brindisi MC, Pais de Barros JP, Lagrost L, Gambert P, Duvillard L.

    J Lipid Res. 2009 Jun;50(6):1209-15. Epub 2009 Jan 22.PMID: 19168444 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.

    Rosenson RS, Otvos JD, Hsia J.

    Diabetes Care. 2009 Jun;32(6):1087-91. Epub 2009 Mar 5.PMID: 19265025 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

    Chan DC, Watts GF, Nguyen MN, Barrett PH.

    Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):590-6. Epub 2006 Jan 12.PMID: 16410456 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.

    Chong T, Naples M, Federico L, Taylor D, Smith GJ, Cheung RC, Adeli K.

    Atherosclerosis. 2006 Mar;185(1):21-31. Epub 2005 Jul 5.PMID: 16002078 [PubMed - indexed for MEDLINE]Related articles

    12.

    Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.

    Le NA, Gibson JC, Ginsberg HN.

    J Lipid Res. 1988 May;29(5):669-77.PMID: 3411241 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.

    Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH.

    Metabolism. 2002 Aug;51(8):1041-6.PMID: 12145779 [PubMed - indexed for MEDLINE]Related articles

    14.

    Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

    Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G.

    J Clin Endocrinol Metab. 2004 Aug;89(8):3949-55.PMID: 15292332 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.

    Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW.

    Am J Cardiol. 2003 Mar 6;91(5A):25C-27C; discussion 28C.PMID: 12646342 [PubMed - indexed for MEDLINE]Related articles

    16.

    Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

    Millar JS, Duffy D, Gadi R, Bloedon LT, Dunbar RL, Wolfe ML, Movva R, Shah A, Fuki IV, McCoy M, Harris CJ, Wang MD, Howey DC, Rader DJ.

    Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6. Epub 2008 Nov 6.PMID: 18988892 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.

    Chan DC, Watts GF, Ng TW, Yamashita S, Barrett PH.

    Eur J Clin Invest. 2008 Oct;38(10):743-51.PMID: 18837799 [PubMed - indexed for MEDLINE]Related articles

    18.

    Physiologic mechanisms of action of lovastatin in nephrotic syndrome.

    Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.

    J Lipid Res. 1995 Jan;36(1):188-99.PMID: 7706943 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

    Onat A, Hergenç G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G.

    Atherosclerosis. 2003 May;168(1):81-9.PMID: 12732390 [PubMed - indexed for MEDLINE]Related articles

    20.

    The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators.

    Curr Med Res Opin. 2005 Aug;21(8):1307-15.PMID: 16083541 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity